PharmaVigilant introduced the latest version of its leading electronic Trial Master File system, I-Vault 2.6. The new enhancements addresses sponsors needs in customized workflow, bulk imports and improved reporting.
“Since its inception, I-Vault eTMF was designed to collect, manage, and organize all documents relating to a sponsors clinical trial or program.” I-Vault 2.6 now offers barcode recognition technology that will read barcode(s) from scanned files. By adding barcodes to our system generated Source Worksheets for example, users have the ability to do bulk or batch scans into I-Vault, which reads the file’s barcode and determines where the document should be placed within the system. This feature enhances our remote Source Document Verification service, streamlining the scanning process so documents are available in their correct placeholders sooner for EDC comparison.
With new OCR capability, I-Vault can now capture the contents of a scanned document and store it within the system. This allows users to convert their paper documents into searchable PDFs for text search purposes. This functionality also enables you to quickly locate content within the system based on a keyword search.
The enhancement to system notifications creates a more user based system with alerts and views of data catered to the authenticated user. When a notification is now created, it can be specified whether it should be sent to the user responsible for reviewing the document via email. This in turn eases the ability to monitor the TMF content across the life of the study.
I-Vault 2.6 also configures document dependencies to streamline the workflow. The Sponsor can now set the system to require a certain document or folder upon the upload or modified status of another document. Additionally, it can be specified whether certain document types require translations.
The digital signature feature of the system has been updated to allow I-Vault users to reach wholly electronic workflows through the authorization stage: Signatures are now embedded into the PDF so that information will never become disconnected from the document itself. This ensures that end users can easily verify and retain proof of identity and document integrity without costly, complicated, or proprietary software. The ability to add multiple signatures to a document is also supported.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.